Primary stenting for acute ischemic stroke using the Enterprise vascular reconstruction device: Early results

Travis M Dumont, Sabareesh K. Natarajan, Jorge L. Eller, J. Mocco, William H. Kelly, Kenneth V. Snyder, L. Nelson Hopkins, Adnan H. Siddiqui, Elad I. Levy

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective: Primary stenting for acute ischemic stroke (AIS) using the Wingspan stent delivery system has been reported. Major technical limitations in that study were difficulties in delivering the device and a few cases in which the Enterprise vascular reconstruction device (stent) was used as a bailout procedure. The Enterprise, which has relatively less radial force and more flexibility than other intracranial stents, is an ideal device for revascularization as it is easily delivered through tortuous intracranial vessels. We tested the safety and effectiveness of this stent as the primary revascularization device for AIS in an FDA-approved investigational device exemption prospective cohort study. Methods: Twenty patients presenting with AIS due to confirmed intracranial large vessel occlusion within 8 h of onset of stroke symptoms were treated with the Enterprise as the primary revascularization device. The primary outcome was recanalization to Thrombolysis In Myocardial Infarction (TIMI) flow of ≥2. Perioperative safety was measured by major complication incidence within 30 days of stent revascularization. A secondary measure of outcome was 30-day modified Rankin Scale (mRS) score. Results: Recanalization to TIMI 2 (n=6) or 3 (n=12) flow was achieved in 18 patients (90% revascularization rate). Three major complications were noted (15%) including one myocardial infarction, one symptomatic intracranial hemorrhage and one ischemic stroke in a distribution other than the qualifying vessel. Good outcome (mRS ≤2) was obtained in 10 patients (50%). Conclusions: In this prospective study the Enterprise stent was found to be a safe and effective revascularization tool in the setting of AIS.

Original languageEnglish (US)
Pages (from-to)363-372
Number of pages10
JournalJournal of NeuroInterventional Surgery
Volume6
Issue number5
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Stents
Blood Vessels
Stroke
Equipment and Supplies
Myocardial Infarction
Prospective Studies
Safety
Intracranial Hemorrhages
Cohort Studies
Outcome Assessment (Health Care)
Incidence

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology
  • Medicine(all)

Cite this

Primary stenting for acute ischemic stroke using the Enterprise vascular reconstruction device : Early results. / Dumont, Travis M; Natarajan, Sabareesh K.; Eller, Jorge L.; Mocco, J.; Kelly, William H.; Snyder, Kenneth V.; Hopkins, L. Nelson; Siddiqui, Adnan H.; Levy, Elad I.

In: Journal of NeuroInterventional Surgery, Vol. 6, No. 5, 2014, p. 363-372.

Research output: Contribution to journalArticle

Dumont, TM, Natarajan, SK, Eller, JL, Mocco, J, Kelly, WH, Snyder, KV, Hopkins, LN, Siddiqui, AH & Levy, EI 2014, 'Primary stenting for acute ischemic stroke using the Enterprise vascular reconstruction device: Early results', Journal of NeuroInterventional Surgery, vol. 6, no. 5, pp. 363-372. https://doi.org/10.1136/neurintsurg-2013-010794
Dumont, Travis M ; Natarajan, Sabareesh K. ; Eller, Jorge L. ; Mocco, J. ; Kelly, William H. ; Snyder, Kenneth V. ; Hopkins, L. Nelson ; Siddiqui, Adnan H. ; Levy, Elad I. / Primary stenting for acute ischemic stroke using the Enterprise vascular reconstruction device : Early results. In: Journal of NeuroInterventional Surgery. 2014 ; Vol. 6, No. 5. pp. 363-372.
@article{ace6e8eb447f44379908c91d3ef5a1cf,
title = "Primary stenting for acute ischemic stroke using the Enterprise vascular reconstruction device: Early results",
abstract = "Objective: Primary stenting for acute ischemic stroke (AIS) using the Wingspan stent delivery system has been reported. Major technical limitations in that study were difficulties in delivering the device and a few cases in which the Enterprise vascular reconstruction device (stent) was used as a bailout procedure. The Enterprise, which has relatively less radial force and more flexibility than other intracranial stents, is an ideal device for revascularization as it is easily delivered through tortuous intracranial vessels. We tested the safety and effectiveness of this stent as the primary revascularization device for AIS in an FDA-approved investigational device exemption prospective cohort study. Methods: Twenty patients presenting with AIS due to confirmed intracranial large vessel occlusion within 8 h of onset of stroke symptoms were treated with the Enterprise as the primary revascularization device. The primary outcome was recanalization to Thrombolysis In Myocardial Infarction (TIMI) flow of ≥2. Perioperative safety was measured by major complication incidence within 30 days of stent revascularization. A secondary measure of outcome was 30-day modified Rankin Scale (mRS) score. Results: Recanalization to TIMI 2 (n=6) or 3 (n=12) flow was achieved in 18 patients (90{\%} revascularization rate). Three major complications were noted (15{\%}) including one myocardial infarction, one symptomatic intracranial hemorrhage and one ischemic stroke in a distribution other than the qualifying vessel. Good outcome (mRS ≤2) was obtained in 10 patients (50{\%}). Conclusions: In this prospective study the Enterprise stent was found to be a safe and effective revascularization tool in the setting of AIS.",
author = "Dumont, {Travis M} and Natarajan, {Sabareesh K.} and Eller, {Jorge L.} and J. Mocco and Kelly, {William H.} and Snyder, {Kenneth V.} and Hopkins, {L. Nelson} and Siddiqui, {Adnan H.} and Levy, {Elad I.}",
year = "2014",
doi = "10.1136/neurintsurg-2013-010794",
language = "English (US)",
volume = "6",
pages = "363--372",
journal = "Journal of NeuroInterventional Surgery",
issn = "1759-8478",
publisher = "BMJ Publishing Group",
number = "5",

}

TY - JOUR

T1 - Primary stenting for acute ischemic stroke using the Enterprise vascular reconstruction device

T2 - Early results

AU - Dumont, Travis M

AU - Natarajan, Sabareesh K.

AU - Eller, Jorge L.

AU - Mocco, J.

AU - Kelly, William H.

AU - Snyder, Kenneth V.

AU - Hopkins, L. Nelson

AU - Siddiqui, Adnan H.

AU - Levy, Elad I.

PY - 2014

Y1 - 2014

N2 - Objective: Primary stenting for acute ischemic stroke (AIS) using the Wingspan stent delivery system has been reported. Major technical limitations in that study were difficulties in delivering the device and a few cases in which the Enterprise vascular reconstruction device (stent) was used as a bailout procedure. The Enterprise, which has relatively less radial force and more flexibility than other intracranial stents, is an ideal device for revascularization as it is easily delivered through tortuous intracranial vessels. We tested the safety and effectiveness of this stent as the primary revascularization device for AIS in an FDA-approved investigational device exemption prospective cohort study. Methods: Twenty patients presenting with AIS due to confirmed intracranial large vessel occlusion within 8 h of onset of stroke symptoms were treated with the Enterprise as the primary revascularization device. The primary outcome was recanalization to Thrombolysis In Myocardial Infarction (TIMI) flow of ≥2. Perioperative safety was measured by major complication incidence within 30 days of stent revascularization. A secondary measure of outcome was 30-day modified Rankin Scale (mRS) score. Results: Recanalization to TIMI 2 (n=6) or 3 (n=12) flow was achieved in 18 patients (90% revascularization rate). Three major complications were noted (15%) including one myocardial infarction, one symptomatic intracranial hemorrhage and one ischemic stroke in a distribution other than the qualifying vessel. Good outcome (mRS ≤2) was obtained in 10 patients (50%). Conclusions: In this prospective study the Enterprise stent was found to be a safe and effective revascularization tool in the setting of AIS.

AB - Objective: Primary stenting for acute ischemic stroke (AIS) using the Wingspan stent delivery system has been reported. Major technical limitations in that study were difficulties in delivering the device and a few cases in which the Enterprise vascular reconstruction device (stent) was used as a bailout procedure. The Enterprise, which has relatively less radial force and more flexibility than other intracranial stents, is an ideal device for revascularization as it is easily delivered through tortuous intracranial vessels. We tested the safety and effectiveness of this stent as the primary revascularization device for AIS in an FDA-approved investigational device exemption prospective cohort study. Methods: Twenty patients presenting with AIS due to confirmed intracranial large vessel occlusion within 8 h of onset of stroke symptoms were treated with the Enterprise as the primary revascularization device. The primary outcome was recanalization to Thrombolysis In Myocardial Infarction (TIMI) flow of ≥2. Perioperative safety was measured by major complication incidence within 30 days of stent revascularization. A secondary measure of outcome was 30-day modified Rankin Scale (mRS) score. Results: Recanalization to TIMI 2 (n=6) or 3 (n=12) flow was achieved in 18 patients (90% revascularization rate). Three major complications were noted (15%) including one myocardial infarction, one symptomatic intracranial hemorrhage and one ischemic stroke in a distribution other than the qualifying vessel. Good outcome (mRS ≤2) was obtained in 10 patients (50%). Conclusions: In this prospective study the Enterprise stent was found to be a safe and effective revascularization tool in the setting of AIS.

UR - http://www.scopus.com/inward/record.url?scp=84901916924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901916924&partnerID=8YFLogxK

U2 - 10.1136/neurintsurg-2013-010794

DO - 10.1136/neurintsurg-2013-010794

M3 - Article

C2 - 23821672

AN - SCOPUS:84901916924

VL - 6

SP - 363

EP - 372

JO - Journal of NeuroInterventional Surgery

JF - Journal of NeuroInterventional Surgery

SN - 1759-8478

IS - 5

ER -